The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / AMP RA/Lupus Network Shares Its Progress

AMP RA/Lupus Network Shares Its Progress

September 26, 2017 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

CHICAGO—“Why do so many drugs fail in clinical trials?” asked Michael Brenner, MD, chief of rheumatology, immunology and allergy at Brigham and Women’s Hospital in Boston. This question, previously posed by Francis Collins, MD, PhD, director of the National Institutes of Health, prompted a discussion among scientists and stakeholders in the pharmaceutical industry. The conversation led to the foundation of the Accelerating Medicines Partnership (AMP) by the National Institutes of Health (NIH), pharmaceutical companies and nonprofit organizations. The partners have designed a project plan to address relevant challenges for rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) through the AMP RA/SLE Program. The goal is to ascertain and define shared and disease-specific biological pathways in order to identify relevant drug targets for the treatment of autoimmune diseases.

You Might Also Like
  • Accelerating Medicines Partnership Shares Its Progress on RA/Lupus Network
  • Accelerating Medicines Partnership Targets Therapies for Rheumatoid Arthritis, Systemic Lupus Erythematosus
  • Precision Medicine for Lupus Continues to Progress
Also By This Author
  • Insights into Celiac Disease & Systemic Autoimmune Diseases

In September 2014, the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and the National Institute of Allergy and Infectious Diseases (NIAID), as participating members of the AMP RA/SLE Program, funded a collaborative AMP RA/Lupus Network.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Researchers from the AMP RA/Lupus Network came together in June at the annual Federation of Clinical Immunology Societies (FOCIS) meeting to share their progress as they perform a systematic molecular deconstruction of human diseases. The network includes both an RA disease group and an SLE disease group. Both groups share the same ultimate goal: to identify biomarkers and drug targets. As they work toward this goal, the network will generate publically accessible, disease-specific data.

The partnership began with the development of a project plan designed to address the relevant challenges of RA and lupus. After the plan has been implemented and data generated, the groups will use system-level bioinformatics to analyze gene expression and signaling in target tissues from affected end organs. The AMP RA/SLE Program has three research phases. “We just finished Phase I a couple of months ago. … We haven’t actually analyzed much of the data for biological insights,” explained Dr. Brenner.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Despite the relative lack of data, the accomplishments have been many, and he and his colleagues talked the audience through the process.

Project Overview
The Network focuses on human tissue and paired blood, and analyzes samples using single-cell and cell-subset approaches. The researchers then pair this analysis with histological, genetic and epigenetic approaches, as budget allows. Both the RA and the SLE groups have progressed similarly, and their efforts differ primarily in the target tissue (synovium vs. kidney). This story focuses on the RA disease group.

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis, SLE (Lupus) Tagged With: Accelerating Medicines Partnership, Lupus, National Institutes of Health (NIH), Rheumatoid Arthritis (RA), systemic lupus erythematosus (SLE)

You Might Also Like:
  • Accelerating Medicines Partnership Shares Its Progress on RA/Lupus Network
  • Accelerating Medicines Partnership Targets Therapies for Rheumatoid Arthritis, Systemic Lupus Erythematosus
  • Precision Medicine for Lupus Continues to Progress
  • Patients with Lupus: Plasmacytoid Dendritic Cells Fail to Induce Regulatory B Cells

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)